7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kumamoto H and Ooya K | Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. | 2004 | J. Oral Pathol. Med. | pmid:14675140 |
| Suda T and Miyaura C | [Recent advance in basic research for osteoporosis]. | 2004 | Nippon Rinsho | pmid:15035090 |
| Matsumoto T | [Recent advances in the regulation of bone remodeling]. | 2004 | Nippon Rinsho | pmid:15035093 |
| Okumura S et al. | [Regulatory mechanism of osteoclast differentiation and function]. | 2004 | Nippon Rinsho | pmid:15035103 |
| Udagawa N et al. | [Possible role of RANKL in bone resorption]. | 2004 | Nippon Rinsho | pmid:15035104 |
| Inoue D | [OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)]. | 2004 | Nippon Rinsho | pmid:15035105 |
| Suzuki Y | [Stimulator of bone resorption interleukin-1, interleukin-6 and gp-130 cytokine family]. | 2004 | Nippon Rinsho | pmid:15035106 |
| Miyaura C | [LPS]. | 2004 | Nippon Rinsho | pmid:15035108 |
| Tanaka Y | [Adhesion molecules in the context with bone remodeling and osteoporosis]. | 2004 | Nippon Rinsho | pmid:15035110 |
| Naumann U et al. | Expression and functional activity of osteoprotegerin in human malignant gliomas. | 2004 | Acta Neuropathol. | pmid:14504888 |
| Wise GE et al. | Regulation of secretion of osteoprotegerin in rat dental follicle cells. | 2004 | Eur. J. Oral Sci. | pmid:15458504 |
| Dai SM et al. | Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. | 2004 | Ann. Rheum. Dis. | pmid:15479886 |
| Wang JC et al. | Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). | 2004 | Exp. Hematol. | pmid:15504545 |
| Chen Q et al. | Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. | 2004 | Horm. Metab. Res. | pmid:15523591 |
| Sato T et al. | Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. | 2004 | Am. J. Hematol. | pmid:15307108 |
| Giuliani N et al. | New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). | 2004 | Exp. Hematol. | pmid:15308315 |
| Colucci S et al. | T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. | 2004 | Blood | pmid:15308561 |
| Miyazaki T et al. | Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. | 2004 | J. Cell. Biochem. | pmid:15372622 |
| Jeffcoate W | Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? | 2004 | Diabetologia | pmid:15322748 |
| Liu Z et al. | Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. | 2004 | Protein Pept. Lett. | pmid:15327363 |
| Politou M et al. | Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). | 2004 | Br. J. Haematol. | pmid:15327520 |
| Erdogan B et al. | Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. | 2004 | Neurol. Res. | pmid:15327755 |
| Kazama JJ | Osteoprotegerin and bone mineral metabolism in renal failure. | 2004 | Curr. Opin. Nephrol. Hypertens. | pmid:15199291 |
| Walsh NC and Gravallese EM | Bone loss in inflammatory arthritis: mechanisms and treatment strategies. | 2004 | Curr Opin Rheumatol | pmid:15201606 |
| Terpos E et al. | Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. | 2004 | Leukemia | pmid:15215875 |
| Brändström H et al. | A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). | 2004 | Blood Press. | pmid:15223723 |
| Wilson SE et al. | RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. | 2004 | Invest. Ophthalmol. Vis. Sci. | pmid:15223796 |
| Pioletti DP and Kottelat A | The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. | 2004 | Biomaterials | pmid:15172492 |
| Livshits G et al. | Genetic influences on the circulating cytokines involved in osteoclastogenesis. | 2004 | J. Med. Genet. | pmid:15173242 |
| De Wilde A et al. | A low dose of daidzein acts as an ERbeta-selective agonist in trabecular osteoblasts of young female piglets. | 2004 | J. Cell. Physiol. | pmid:15174095 |
| Lee CK et al. | Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. | 2004 | Arthritis Rheum. | pmid:15593184 |
| Grzegorzewska AE and MÅ‚ot M | Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631341 |
| Grzegorzewska AE and MÅ‚ot M | Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631342 |
| Naumnik W et al. | Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15638385 |
| Eaton CL et al. | Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. | 2004 | Prostate | pmid:15042606 |
| O' Gradaigh D et al. | Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. | 2004 | Ann. Rheum. Dis. | pmid:15020327 |
| Collantes Estévez E and González DomÃnguez J | [Bone Paget's disease in the young adult]. | 2004 | Rev Clin Esp | pmid:15456600 |
| Kyrtsonis MC et al. | Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. | 2004 | Eur. J. Haematol. | pmid:15089762 |
| Miao D et al. | Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. | 2004 | Endocrinology | pmid:15090463 |
| Haynes DR et al. | Regulation of osteoclast activity in peri-implant tissues. | 2004 | Biomaterials | pmid:15109848 |
| Ito S and Hata T | Crystal structure of RANK ligand involved in bone metabolism. | 2004 | Vitam. Horm. | pmid:15110169 |
| Hao C et al. | Modulation of TRAIL signaling complex. | 2004 | Vitam. Horm. | pmid:15110173 |
| Kiechl S et al. | Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. | 2004 | Circulation | pmid:15117849 |
| Altun A et al. | Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. | 2004 | J. Endocrinol. Invest. | pmid:15648548 |
| Kanzaki H et al. | Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement. | 2004 | J. Dent. Res. | pmid:15557398 |
| Ambroszkiewicz J et al. | [Biochemical bone resorption markers in children with osteosarcoma]. | 2004 Apr-Jun | Med Wieku Rozwoj | pmid:15738598 |
| Dovio A et al. | [Pathophysiological significance and clinical utility of circulating osteoprotegerin]. | 2004 Jan-Mar | Ann. Ital. Med. Int. | pmid:15176704 |
| Oh ES et al. | Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. | 2005 | Metab. Clin. Exp. | pmid:15562379 |
| Rajzbaum G et al. | French women, fractures and aortic calcifications. | 2005 | J. Intern. Med. | pmid:15606383 |
| Al-Fakhri N et al. | Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification. | 2005 | Thromb. Haemost. | pmid:16411417 |
| Jiang J et al. | LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL. | 2005 | Artif Cells Blood Substit Immobil Biotechnol | pmid:16317958 |
| Galluzzi F et al. | Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. | 2005 | Eur. J. Endocrinol. | pmid:16322394 |
| Raisz LG | Pathogenesis of osteoporosis: concepts, conflicts, and prospects. | 2005 | J. Clin. Invest. | pmid:16322775 |
| Kieslinger M et al. | EBF2 regulates osteoblast-dependent differentiation of osteoclasts. | 2005 | Dev. Cell | pmid:16326388 |
| Yamazaki H and Sasaki T | Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice. | 2005 | J Electron Microsc (Tokyo) | pmid:16339792 |
| Pantsulaia I et al. | Contribution of the familial and genetic factors on monocyte chemoattractant protein-1 variation in healthy human pedigrees. | 2005 | Cytokine | pmid:16213155 |
| Low E et al. | Expression of mRNA for osteoprotegerin and receptor activator of nuclear factor kappa beta ligand (RANKL) during root resorption induced by the application of heavy orthodontic forces on rat molars. | 2005 | Am J Orthod Dentofacial Orthop | pmid:16214633 |
| Schneeweis LA et al. | Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. | 2005 | J. Biol. Chem. | pmid:16215261 |
| Bezerra MC et al. | Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. | 2005 | Rheumatology (Oxford) | pmid:16219645 |
| Zwerina J et al. | Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. | 2005 | FASEB J. | pmid:16234431 |
| Viereck V et al. | Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. | 2005 | J. Bone Miner. Res. | pmid:16234977 |
| Gajewska J et al. | [The impairement of bone formation and resorption in 25-year-old man with neglected celiac disease]. | 2005 | Wiad. Lek. | pmid:16238129 |
| Li J et al. | [Effect of raloxifene and estradiol on the biological function and osteoprotegerin expression of osteoblasts in vitro]. | 2005 | Di Yi Jun Yi Da Xue Xue Bao | pmid:16027068 |
| Pipes GD et al. | Optimization and applications of CDAP labeling for the assignment of cysteines. | 2005 | Pharm. Res. | pmid:16028006 |
| Yang S et al. | Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts. | 2005 | J. Immunol. | pmid:16034140 |
| Mangashetti LS et al. | IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling. | 2005 | J. Immunol. | pmid:16002690 |
| Lukić IK et al. | Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1. | 2005 | Clin. Exp. Immunol. | pmid:15654822 |
| Subramaniam M et al. | TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. | 2005 | Mol. Cell. Biol. | pmid:15657444 |
| Mesquita M et al. | Bone cytokines and renal osteodystrophy in peritoneal dialysis patients. | 2005 | Adv Perit Dial | pmid:16686314 |
| Glass DA et al. | Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. | 2005 | Dev. Cell | pmid:15866165 |
| Grzegorzewska AE and Mlot M | Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients. | 2005 | Adv Perit Dial | pmid:16686316 |
| Valenta A et al. | Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. | 2005 | Bone | pmid:15869920 |
| Chan MH et al. | Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. | 2005 | Pathology | pmid:15875734 |
| Seminari E et al. | Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. | 2005 | HIV Med. | pmid:15876279 |
| Abrahamsen B et al. | Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. | 2005 | Bone | pmid:15781001 |
| Schett G et al. | Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. | 2005 | Arthritis Rheum. | pmid:15880601 |
| Zhao HY et al. | The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. | 2005 | Osteoporos Int | pmid:15782282 |
| Moe SM et al. | Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). | 2005 | Kidney Int. | pmid:15882271 |
| Bezerra MC et al. | RANK, RANKL and osteoprotegerin in arthritic bone loss. | 2005 | Braz. J. Med. Biol. Res. | pmid:15785827 |
| Ueland T et al. | Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. | 2005 | Circulation | pmid:15883214 |
| Stilgren LS et al. | [The cytokine system of bone tissue]. | 2005 | Ugeskr. Laeg. | pmid:15789838 |
| Fukushima H et al. | Parathyroid-hormone-related protein induces expression of receptor activator of NF-{kappa}B ligand in human periodontal ligament cells via a cAMP/protein kinase A-independent pathway. | 2005 | J. Dent. Res. | pmid:15790738 |
| Konduri K et al. | Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression. | 2005 | Clin Lymphoma | pmid:15794867 |
| Bord S et al. | Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. | 2005 | Bone | pmid:15794927 |
| Xie F et al. | Increase in bone mass and bone strength by Sambucus williamsii HANCE in ovariectomized rats. | 2005 | Biol. Pharm. Bull. | pmid:16204939 |
| Juarranz Y et al. | Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. | 2005 | Arthritis Res. Ther. | pmid:16207319 |
| Kerschan-Schindl K et al. | Serum levels of cathepsin K decrease with age in both women and men. | 2005 | Exp. Gerontol. | pmid:15935595 |
| Görtz B et al. | Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. | 2005 | Arthritis Res. Ther. | pmid:16207331 |
| Ugur-Altun B et al. | The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. | 2005 | Diabetes Res. Clin. Pract. | pmid:15936463 |
| Kostenuik PJ | Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. | 2005 | Curr Opin Pharmacol | pmid:16188502 |
| Whang PG et al. | The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. | 2005 | J. Orthop. Res. | pmid:16005175 |
| Sakakura Y et al. | Immunolocalization of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) in Meckel's cartilage compared with developing endochondral bones in mice. | 2005 | J. Anat. | pmid:16191162 |
| Oh KW et al. | Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. | 2005 | Clin. Endocrinol. (Oxf) | pmid:15638876 |
| Bashir A et al. | Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. | 2005 | Steroids | pmid:16005483 |
| Meng XM et al. | [Expression of receptor activator of NF-kappa B ligand and osteoprotegerin protein in the giant cell lesions of jaw]. | 2005 | Zhonghua Kou Qiang Yi Xue Za Zhi | pmid:16191370 |
| Khosla S | Magic bullets to kill nasty osteoclasts. | 2005 | Endocrinology | pmid:16009971 |
| Tabuchi M et al. | Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. | 2005 | Calcif. Tissue Int. | pmid:16193235 |
| Ketteler M et al. | "Missing" inhibitors of calcification: general aspects and implications in renal failure. | 2005 | Pediatr. Nephrol. | pmid:15549415 |
| Feng X | RANKing intracellular signaling in osteoclasts. | 2005 | IUBMB Life | pmid:16012047 |
| Rhee EJ et al. | Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. | 2005 | Clin. Sci. | pmid:15569000 |